Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa

Tersia Kruger, D. Szabó, Karen H. Keddy, Kathleen Deeley, Jane W. Marsh, Andrea M. Hujer, Robert A. Bonomo, David L. Paterson

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Salmonella spp. producing extended-spectrum beta-lactamases (ESBLs) have been reported in many countries, but there is no information on their prevalence in Africa. ESBL-producing Salmonella enterica serotype Isangi and S. enterica serotype Typhimurium strains have been noted in South Africa since 2001. A total of 160 consecutive isolates of Salmonella spp. were collected from 13 hospitals located in different cities in South Africa over a 5-month period from December 2002 to April 2003. All strains were screened for production of ESBLs by the double disk diffusion test and for AmpC production by assessing resistance to cefoxitin. blaSHV, blaTEM, blaCTX-M, and blaCMY-2 were sought from all ESBL-positive and cefoxitin-resistant isolates. A total of 15.6% (25 of 160) isolates produced SHV or TEM ESBLs, and 1.9% (3 of 160) produced CMY-2. Nine S. enterica serotype Typhimurium, eight S. enterica serotype Isangi, and three S. enterica serotype Muenchen strains produced either TEM-63 or a derivative of TEM-63 designated TEM-131. Both TEM-63 and TEM-131 have an isoelectric point of 5.6, and their sequences have the following amino acid substitutions compared to the TEM-1 sequence: Leu21Phe, Glu104Lys, Arg164Ser, and Met182Thr. Additionally, TEM-131 has an Ala237Thr substitution. ESBL-producing Salmonella spp. have become a significant public health problem in South Africa with particular implications for the treatment of serious nontyphoidal Salmonella infections in children, for whom extended-spectrum cephalosporins were the preferred treatment.

Original languageEnglish
Pages (from-to)4263-4270
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number11
DOIs
Publication statusPublished - Nov 2004

Fingerprint

beta-Lactamases
South Africa
Salmonella enterica
Salmonella
Enzymes
Infection
Cefoxitin
Salmonella Infections
Isoelectric Point
Amino Acid Substitution
Cephalosporins
Public Health
Serogroup
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. / Kruger, Tersia; Szabó, D.; Keddy, Karen H.; Deeley, Kathleen; Marsh, Jane W.; Hujer, Andrea M.; Bonomo, Robert A.; Paterson, David L.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 11, 11.2004, p. 4263-4270.

Research output: Contribution to journalArticle

Kruger, Tersia ; Szabó, D. ; Keddy, Karen H. ; Deeley, Kathleen ; Marsh, Jane W. ; Hujer, Andrea M. ; Bonomo, Robert A. ; Paterson, David L. / Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 11. pp. 4263-4270.
@article{4dc3af888c57440e838265f9490d1d81,
title = "Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa",
abstract = "Salmonella spp. producing extended-spectrum beta-lactamases (ESBLs) have been reported in many countries, but there is no information on their prevalence in Africa. ESBL-producing Salmonella enterica serotype Isangi and S. enterica serotype Typhimurium strains have been noted in South Africa since 2001. A total of 160 consecutive isolates of Salmonella spp. were collected from 13 hospitals located in different cities in South Africa over a 5-month period from December 2002 to April 2003. All strains were screened for production of ESBLs by the double disk diffusion test and for AmpC production by assessing resistance to cefoxitin. blaSHV, blaTEM, blaCTX-M, and blaCMY-2 were sought from all ESBL-positive and cefoxitin-resistant isolates. A total of 15.6{\%} (25 of 160) isolates produced SHV or TEM ESBLs, and 1.9{\%} (3 of 160) produced CMY-2. Nine S. enterica serotype Typhimurium, eight S. enterica serotype Isangi, and three S. enterica serotype Muenchen strains produced either TEM-63 or a derivative of TEM-63 designated TEM-131. Both TEM-63 and TEM-131 have an isoelectric point of 5.6, and their sequences have the following amino acid substitutions compared to the TEM-1 sequence: Leu21Phe, Glu104Lys, Arg164Ser, and Met182Thr. Additionally, TEM-131 has an Ala237Thr substitution. ESBL-producing Salmonella spp. have become a significant public health problem in South Africa with particular implications for the treatment of serious nontyphoidal Salmonella infections in children, for whom extended-spectrum cephalosporins were the preferred treatment.",
author = "Tersia Kruger and D. Szab{\'o} and Keddy, {Karen H.} and Kathleen Deeley and Marsh, {Jane W.} and Hujer, {Andrea M.} and Bonomo, {Robert A.} and Paterson, {David L.}",
year = "2004",
month = "11",
doi = "10.1128/AAC.48.11.4263-4270.2004",
language = "English",
volume = "48",
pages = "4263--4270",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa

AU - Kruger, Tersia

AU - Szabó, D.

AU - Keddy, Karen H.

AU - Deeley, Kathleen

AU - Marsh, Jane W.

AU - Hujer, Andrea M.

AU - Bonomo, Robert A.

AU - Paterson, David L.

PY - 2004/11

Y1 - 2004/11

N2 - Salmonella spp. producing extended-spectrum beta-lactamases (ESBLs) have been reported in many countries, but there is no information on their prevalence in Africa. ESBL-producing Salmonella enterica serotype Isangi and S. enterica serotype Typhimurium strains have been noted in South Africa since 2001. A total of 160 consecutive isolates of Salmonella spp. were collected from 13 hospitals located in different cities in South Africa over a 5-month period from December 2002 to April 2003. All strains were screened for production of ESBLs by the double disk diffusion test and for AmpC production by assessing resistance to cefoxitin. blaSHV, blaTEM, blaCTX-M, and blaCMY-2 were sought from all ESBL-positive and cefoxitin-resistant isolates. A total of 15.6% (25 of 160) isolates produced SHV or TEM ESBLs, and 1.9% (3 of 160) produced CMY-2. Nine S. enterica serotype Typhimurium, eight S. enterica serotype Isangi, and three S. enterica serotype Muenchen strains produced either TEM-63 or a derivative of TEM-63 designated TEM-131. Both TEM-63 and TEM-131 have an isoelectric point of 5.6, and their sequences have the following amino acid substitutions compared to the TEM-1 sequence: Leu21Phe, Glu104Lys, Arg164Ser, and Met182Thr. Additionally, TEM-131 has an Ala237Thr substitution. ESBL-producing Salmonella spp. have become a significant public health problem in South Africa with particular implications for the treatment of serious nontyphoidal Salmonella infections in children, for whom extended-spectrum cephalosporins were the preferred treatment.

AB - Salmonella spp. producing extended-spectrum beta-lactamases (ESBLs) have been reported in many countries, but there is no information on their prevalence in Africa. ESBL-producing Salmonella enterica serotype Isangi and S. enterica serotype Typhimurium strains have been noted in South Africa since 2001. A total of 160 consecutive isolates of Salmonella spp. were collected from 13 hospitals located in different cities in South Africa over a 5-month period from December 2002 to April 2003. All strains were screened for production of ESBLs by the double disk diffusion test and for AmpC production by assessing resistance to cefoxitin. blaSHV, blaTEM, blaCTX-M, and blaCMY-2 were sought from all ESBL-positive and cefoxitin-resistant isolates. A total of 15.6% (25 of 160) isolates produced SHV or TEM ESBLs, and 1.9% (3 of 160) produced CMY-2. Nine S. enterica serotype Typhimurium, eight S. enterica serotype Isangi, and three S. enterica serotype Muenchen strains produced either TEM-63 or a derivative of TEM-63 designated TEM-131. Both TEM-63 and TEM-131 have an isoelectric point of 5.6, and their sequences have the following amino acid substitutions compared to the TEM-1 sequence: Leu21Phe, Glu104Lys, Arg164Ser, and Met182Thr. Additionally, TEM-131 has an Ala237Thr substitution. ESBL-producing Salmonella spp. have become a significant public health problem in South Africa with particular implications for the treatment of serious nontyphoidal Salmonella infections in children, for whom extended-spectrum cephalosporins were the preferred treatment.

UR - http://www.scopus.com/inward/record.url?scp=7244231224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244231224&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.11.4263-4270.2004

DO - 10.1128/AAC.48.11.4263-4270.2004

M3 - Article

VL - 48

SP - 4263

EP - 4270

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -